The company is demonstrably advanced the development of a new treatment for cardiac amyloidosis, leveraging Attruby. Preliminary clinical data reveals potential outcomes for those suffering with this serious disease. https://attruby352612.smblogsites.com/42213963/bridgebio-progresses-attr-cm-treatment-with-the-drug